Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Olaparib Plus Trastuzumab in HER2+ BRCA-mutated Advanced Breast Cancer
NCT03931551Phase 2Terminated
- Sponsor
- MEDSIR
- Start
- Apr 2019
- Primary completion
- Mar 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of olaparib in breast cancer, sponsored by MEDSIR. Primary endpoint: Efficacy of olaparib in combination with trastuzumab at 12 months. Started Apr 2019; status: terminated.
02
Drugs
olaparib
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT03931551.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03931551.